TRiCares SAS has announced the first implantation of its Topaz transfemoral tricuspid heart valve replacement system in a pivotal study in Europe. The TRICURE European pivotal study is taking place at sites in Germany, Belgium, France and Switzerland, with additional countries expected to follow. The study will assess the safety and efficacy of Topaz in patients with significant tricuspid regurgitation (TR) who are not candidates for open heart …
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.